Durham, NC (July 12, 2019) - Symberix is profiled in a new Nature Reviews article on companies developing microbiome-modulating small-molecule drugs. The article highlights our novel therapeutic approach and includes quotes from our co-founder, Dr. Matt Redinbo.
The full article is published at Nature Reviews Drug Discovery .
Contact: Greg Mossinghoff Chief Business Officer Symberix, Inc. [email protected]
Symberix, Inc. 4819 Emperor Blvd, #400 Durham, NC 27703
Icons by icons8 .